Allakos Inc.

Allakos Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Allakos Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Allakos Inc..

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a...

News

Allakos (NASDAQ:ALLK) Trading 2.1% Higher

Zolmax Allakos Inc. (NASDAQ:ALLK - Get Free Report)'s stock price was up 2.1% during trading on Monday . The company traded as high as $0.68 and last traded at $0.65. Approximately 359,983 shares traded...\n more…

Reviewing Allakos (NASDAQ:ALLK) and CNBX Pharmaceuticals (OTCMKTS:CNBX)

Ticker Report CNBX Pharmaceuticals (OTCMKTS:CNBX - Get Free Report) and Allakos (NASDAQ:ALLK - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies...\n more…

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Simply Wall St We can readily understand why investors are attracted to unprofitable companies. For example, although...\n more…

Vanguard Group Inc. Raises Stock Holdings in Allakos Inc. (NASDAQ:ALLK)

Zolmax Vanguard Group Inc. lifted its holdings in Allakos Inc. (NASDAQ:ALLK - Free Report) by 16.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The...\n more…

FY2024 EPS Estimates for Allakos Inc. (NASDAQ:ALLK) Boosted by Analyst

Ticker Report Allakos Inc. (NASDAQ:ALLK - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of Allakos in a report released on Thursday...\n more…

William Blair Analysts Boost Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)

Ticker Report Allakos Inc. (NASDAQ:ALLK - Free Report) - William Blair increased their Q3 2024 earnings estimates for shares of Allakos in a research report issued on Wednesday, August 7th. William Blair analyst...\n more…